Q2
BSX — Q2 2026 Financial Report Analysis
Boston Scientific beat Q2 2026 guidance with sales up 7.5% to $5.44B and adjusted EPS of $0.86, but Electrophysiology and Watchman growth slowed sharply, full-year guidance was cut, and an August cyberattack has since put even that outlook out of reach.